WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
WEGOVY
Date registered
Evaluation commenced
Decision date
Approval time
220 (255 working days)
Active ingredients
Semaglutide
Registration type
EOI
Indication
Reduction in risk of major adverse cardiovascular events
Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) ≥27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties – Clinical trials).